Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Novo Nordisk A/S Common Stock (NY:NVO)

49.11 -0.35 (-0.71%)
Official Closing Price Updated: 6:30 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Weight Loss Drugs Are Quietly Exploding Employer Health Insurance Costs: 'There Is A Quiet Alarm Bell Going Off'
Employer-sponsored health insurance costs rise for third year, with average family premiums at $27,000 in 2025. Drug costs and GLP-1s drive spending. 
Via Benzinga
Marjorie Taylor Greene Buys 6 Stocks And Bitcoin ETF: Here's Her Latest Shopping List
Congresswoman Marjorie Taylor Greene (R-Ga.) is among the most active traders in Congress. Here's a look at her latest trades disclosed, which comes with increased attention on Congress Trades from... 
Via Benzinga
Novo Nordisk Shares Tumble Amid Sweeping Board Overhaul
Copenhagen, Denmark – October 22, 2025 – Novo Nordisk (NYSE: NVO) shares experienced a notable decline this week following the announcement of a comprehensive board overhaul, a decisive move... 
Via MarketMinute
Topics Economy Government Intellectual Property
Omeros Corp Stock Soars A Whopping 136% Pre-Market After Novo Nordisk Agrees To Buy Its Drug Candidate For Blood Disorder
Via Stocktwits
3 Things Investors Need to Know Ahead of Eli Lilly's Q3 Earnings Report
The rapid growth rates of recent years aren't guaranteed to continue. 
Via The Motley Fool
Topics Intellectual Property
These 3 Beaten-Down Healthcare Stocks Could Have Farther to Fall
Don't try to catch a falling surgical knife. 
Via The Motley Fool
Topics Government
Did Eli Lilly Just Say "Checkmate" to Novo Nordisk?
The tides continue to change in Eli Lilly's favor in the GLP-1 space. 
Via The Motley Fool
Behind the Scenes of Novo Nordisk's Latest Options Trends
 
Via Benzinga
2 Beaten-Down Stocks to Buy and Hold for the Next Decade
That's plenty of time for these drugmakers to move past their challenges. 
Via The Motley Fool
These 3 Obesity Drug Stocks Are Set to Soar This Fall and Beyond
These companies are jockeying for position in a potential $150 billion market opportunity. 
Via The Motley Fool
'No Place Is Risk-Free Until The World Is Polio-Free:' Bill Gates Urges Global Action To Close Deadly Immunity Gaps
Polio cases drop 99.9%, but funding shortfall could undo progress. Last mile hardest as virus exploits immunity gaps. 
Via Benzinga
Benzinga Bulls And Bears: Stellantis, Papa John's, Oklo — And Trade Tensions Shake Chip Stocks
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
Topics World Trade
Trump's Weight-Loss Drug Push May Put These ETFs On A Diet
Trump's vow to slash weight-loss drug prices sent Hims & Hers tumbling. These ETFs are facing new pressure. 
Via Benzinga
Topics ETFs Government
Trump-Induced Volatility Aside, Novo Trades Cheap While Patents Protect Its Profits Until 2032
Novo Nordisk offers cheap stock with strong moat and long-term growth tailwinds. Trump's drug price cut suggestion caused short-term volatility but... 
Via Benzinga
Topics Government Intellectual Property
Novo Nordisk Stock Is Falling Friday: What's Driving The Action?
Shares of Danish pharmaceutical giant Novo Nordisk are trading lower Friday morning, continuing an after-hours slide that began Thursday. 
Via Benzinga
Trump Pledges To Cut Obesity Drug Prices. Novo Nordisk, Eli Lilly Stocks Dive.
Novo Nordisk and Eli Lilly stocks slumped Friday after President Donald Trump said he would cut the price of obesity drugs. 
Via Investor's Business Daily
Topics Government
Novo Nordisk Hires US Pharma Veteran After Trump Touts ‘Much Lower’ Prices Of Ozempic
Greg Miley stated that he will join Novo Nordisk next month as the company’s senior vice president of corporate affairs. 
Via Stocktwits
Topics Government
Eli Lilly Shares Are Trading Lower Friday: What's Going On?
Eli Lilly shares are trading lower Friday, among other GLP-1 drug manufacturers, following Trump's comments that fat-loss drugs will be a lot lower in price. 
Via Benzinga
Topics Government
Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs?
Trump's promise to cut cost of Novo Nordisk A/S drug Ozempic from $1,300 to $150 shakes GLP-1 gold rush, with potential impact on Eli Lilly and Pfizer. 
Via Benzinga
Topics Government
Market Jitters: Dow Dips Amid Bank Fears While Eli Lilly and Novo Nordisk Tumble on Trump's Drug Pricing Comments
The financial markets experienced a turbulent Friday, October 17, 2025, as the Dow Jones Industrial Average faced a downturn driven by a resurgence of fears within the banking sector. Concurrently,... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
Regional Banks’ Credit Concerns Drag Dow Futures: NVO, WAL, ZION, IBKR Among Stocks To Watch
While Dow Jones futures were down by 0.13% at the time of writing, the S&P 500 futures declined 0.41%. 
Via Stocktwits
Topics ETFs Earnings Fraud
Eli Lilly vs. Viking Therapeutics Stock: Which Is the Best Growth Opportunity, According to Wall Street?
These stocks have climbed in the triple digits over the past few years. 
Via The Motley Fool
Eli Lilly, Novo Nordisk Stocks Fall After-Hours As Trump Pledges Swift Price Cuts For ‘Fat-Loss Drugs’
Novo Nordisk is also continuing discussions with the administration under the Most Favored Nation policy aimed at linking U.S. drug costs to global benchmarks. 
Via Stocktwits
Topics Economy Government
Eli Lilly, Novo Nordisk, Hims & Hers Health Shares Move Lower After Trump Calls Out 'Fat-Loss Drugs'
Shares of Eli Lilly and Novo Nordisk move lower in Thursday's after-hours session after President Trump indicated weight-loss drugs are going to go down in price. 
Via Benzinga
Topics Government
What's Driving the Market Sentiment Around Novo Nordisk AS?
 
Via Benzinga
Hims & Hers Stock's 150% Surge Is All Fundamentals—No Novo, No Problem
Hims & Hers (HIMS) has seen surprising success, up 150% YTD, driven by their new menopause specialty and refocusing on healthcare. 
Via Benzinga
A Deal With Novo Nordisk Sent This Stock 181% Higher Overnight. Is It a Buy Now?
Find out if the deal Omeros announced is enough of a reason to buy this stock. 
Via The Motley Fool
Omeros Stock Logs Best Session Ever After HC Wainwright Doubles Target On Novo Nordisk Deal; Retail Sees Big Upside
The rally followed H.C. Wainwright’s price target hike to $20 on the back of a $2.1 billion licensing deal with Novo Nordisk for zaltenibart. 
Via Stocktwits
Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
Novo Nordisk’s $4.7B Akero deal boosts its metabolic health pipeline, targeting Eli Lilly’s lead in obesity and liver disease treatments 
Via MarketBeat
Topics World Trade
Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal
Omeros stock jumps 164% as Novo Nordisk acquires global rights to zaltenibart, with potential milestones reaching $2.1 billion and tiered royalties. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.